Actively Recruiting
Randomized Phase 2 Trial of Intralesional L19IL2, L19TNF, or Combination Therapy for Locally Advanced Basal Cell Carcinoma
Led by Philogen S.p.A. · Updated on 2026-07-31
180
Participants Needed
18
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research investigates treatments for patients with locally advanced basal cell carcinoma LaBCC who are not eligible for or refuse surgery or radiation therapy based on a local tumor boards evaluation. The study aims to evaluate the effectiveness of three different immunocytokine therapies L19IL2 alone, L19TNF alone, or a combination of L19IL2 and L19TNF. It is a Phase 2 randomized trial involving patients with measurable cutaneous or subcutaneous lesions. Participants will be randomly assigned to one of three groups receiving intralesional injections of either 13 million IU L19IL2, 0.4 mg L19TNF, or a combination of both, once weekly for four consecutive weeks. Treatments are administered directly into the tumor under medical supervision, with doses adjusted based on lesion size. After treatment, tumor assessments are conducted periodically to evaluate response, including photographic documentation, ultrasound, MRI, and biopsies. Throughout the study, participants undergo tumor evaluation visits at weeks 8, 12, and 16, then every 8 weeks during the first year and every 12 weeks in the second and third years. Confirmatory biopsies verify tumor response. Patients may have surgery if deemed appropriate after response confirmation. Follow-up continues for up to 156 weeks to monitor overall survival and any further treatments. Safety and treatment effects are closely monitored throughout the study duration.
CONDITIONS
Brief Title
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Research Team
L
Lisa Nadal
C
Concetta Aulicino
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here